Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2025-11-12 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-September 2025 for Isofol Medical AB. It contains comprehensive financial data, including income statements, balance sheet items (cash equivalents), and key performance indicators (net sales, earnings per share). It also includes management commentary, clinical trial updates, and operational highlights. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements, it is classified as an Interim/Quarterly Report. 9M 2025
2025-11-12 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report' for the period 'January - September 2025'. It contains detailed financial information, including a table of key figures (Net revenue, Result for the period, Earnings per share, Cash and cash equivalents) for the third quarter and the nine-month period. It also includes management commentary, clinical development updates, and significant events. This meets the criteria for an Interim/Quarterly Report (IR). 9M 2025
2025-11-12 English
Isofol appoints nomination committee ahead of the Annual General Meeting 2026
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a nomination committee for the upcoming 2026 Annual General Meeting. It details the members of the committee and provides instructions for shareholders to submit proposals. This type of disclosure is a standard part of corporate governance and meeting preparation, falling under the category of AGM-related information or general regulatory announcements. Given the specific focus on the nomination committee formation for an AGM, it fits best under AGM-R.
2025-11-04 English
Isofol har utsett valberedning inför årsstämman 2026
Board/Management Information Classification · 100% confidence The document is a press release from Isofol Medical AB announcing the appointment of its nomination committee (valberedning) for the 2026 Annual General Meeting. It details the composition of the committee and provides instructions for shareholders to submit proposals. This type of announcement regarding board-related governance and meeting preparation falls under the category of general regulatory filings or corporate governance announcements, but given the specific nature of the announcement (nomination committee appointment), it is best classified as a Regulatory Filing (RNS) as it does not fit into the specific categories of AGM materials (which are the meeting documents themselves) or Proxy Solicitation.
2025-11-04 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding where Avanza Bank Holding AB has crossed a 10% ownership threshold in Isofol Medical AB. This is a classic major shareholding notification, which corresponds to the 'Major Shareholding Notification' category.
2025-09-23 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) for the period January-June 2025. It contains comprehensive financial statements, key performance indicators (key figures table), management commentary on business trends, clinical trial updates, and financial results. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-08-26 Swedish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.